AR055054A1 - Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina - Google Patents

Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina

Info

Publication number
AR055054A1
AR055054A1 ARP060101596A ARP060101596A AR055054A1 AR 055054 A1 AR055054 A1 AR 055054A1 AR P060101596 A ARP060101596 A AR P060101596A AR P060101596 A ARP060101596 A AR P060101596A AR 055054 A1 AR055054 A1 AR 055054A1
Authority
AR
Argentina
Prior art keywords
dihydro
fluoro
methyl
diclorophenyl
amina
Prior art date
Application number
ARP060101596A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR055054A1 publication Critical patent/AR055054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Así como las composiciones, los procesos de preparacion, y las aplicaciones de estas. Reivindicacion 1: Un polimorfo cristalina (Forma I) de clorhidrato de {[(2R)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzo-furano-2-il]metil} amina, caracterizado porque tiene un patron de difraccion de polvo de rayos X comprendiendo un peak característico, en términos de 2 theta, en alrededor 10,2° y por lo menos un peak característico, en términos de 2 theta, seleccionado alrededor de 27,0° y sobre 25,8°.
ARP060101596A 2005-04-22 2006-04-21 Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina AR055054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67431805P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
AR055054A1 true AR055054A1 (es) 2007-08-01

Family

ID=36609610

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101596A AR055054A1 (es) 2005-04-22 2006-04-21 Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina

Country Status (13)

Country Link
US (1) US20060252825A1 (es)
EP (1) EP1879875A1 (es)
JP (1) JP2008538581A (es)
CN (1) CN101163689A (es)
AR (1) AR055054A1 (es)
AU (1) AU2006239897A1 (es)
BR (1) BRPI0610785A2 (es)
CA (1) CA2603900A1 (es)
GT (1) GT200600158A (es)
MX (1) MX2007013179A (es)
PE (1) PE20061319A1 (es)
TW (1) TW200716583A (es)
WO (1) WO2006116218A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
BRPI0610037A2 (pt) * 2005-04-22 2010-05-25 Wyeth Corp derivados de dihidrobenzofurano e uso dos mesmos
WO2006116150A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
MX2007013026A (es) * 2005-04-22 2008-01-11 Wyeth Corp Combinaciones terapeuticas para el tratamiento o prevencion de trastornos psicoticos.
CN101218223A (zh) * 2005-04-22 2008-07-09 惠氏公司 苯并二烷和苯并二氧戊环衍生物及其应用
CA2605117A1 (en) * 2005-04-22 2006-11-02 Wyeth Treatment of pain
EP1871355A1 (en) * 2005-04-22 2008-01-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
EP1871358A1 (en) * 2005-04-22 2008-01-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
WO2006116136A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
RU2007139541A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные хромана и хромена и их применение
AU2006239941A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
EP3208272B1 (en) 2005-11-08 2020-01-08 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
AR060090A1 (es) * 2006-03-24 2008-05-21 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
RS55559B1 (sr) 2007-12-07 2017-05-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
NZ602838A (en) 2010-04-07 2015-06-26 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2554736A (en) * 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US3513239A (en) * 1967-03-15 1970-05-19 Smithkline Corp Pharmaceutical compositions containing 2-aminoalkyl coumaran derivatives and methods of treating depression therewith
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) * 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4210754A (en) * 1977-02-01 1980-07-01 Hoffmann-La Roche Inc. Morpholino containing benzamides
US4205080A (en) * 1977-07-21 1980-05-27 Shell Oil Company 2,3-Dihydro benzofuran carboxamides
NL7906913A (nl) * 1979-09-17 1981-03-19 Tno Werkwijze en inrichting voor het tot stand brengen van een ionenstroom.
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4436371A (en) * 1981-06-24 1984-03-13 Donnelly Mirrors, Inc. Vehicle mirror assembly
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4992464A (en) * 1987-02-10 1991-02-12 Abbott Laboratories Heteroaryl N-hydroxy amides and ureas with polar substituents as 5-lipoxygenase inhibitors
US5175170A (en) * 1989-12-04 1992-12-29 G. D. Searle & Co. β-amino acid derivatives
US5212175A (en) * 1989-12-04 1993-05-18 G. D. Searle & Co. Benzothiophenyl benzothiophenylalkyl-N-terminal amino hydroxy β-amino acid derivatives
US5215996A (en) * 1989-12-04 1993-06-01 G. D. Searle & Co. Naphthyridinyl/naphthyridinylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
US5217988A (en) * 1989-12-04 1993-06-08 G. D. Searle & Co. Indolyl indolylakyl-N-terminal cycloalkoxy-C-terminal amino hydroxyβ-amino acid derivatives
US5180725A (en) * 1989-12-04 1993-01-19 G. D. Searle & Co. Quinoxalinyl/quinoxaliy; alkyl-N-terminal amino hydroxy
US5223512A (en) * 1989-12-04 1993-06-29 G. D. Searle & Co. Quinolonyl/quinolonylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
US5180744A (en) * 1989-12-04 1993-01-19 G. D. Searle & Co. Aralkyl-N-terminal amino hydroxy
US5217991A (en) * 1989-12-04 1993-06-08 G. D. Searle & Co. Cycloalkyl/cycloalkylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
US5212174A (en) * 1989-12-04 1993-05-18 G. D. Searle & Co. Quinoxalinyl/quinoxalinylakyl-N- terminal cycloalkoxy-C- terminal amino hydroxy β-amino acid derivatives
US5210095A (en) * 1989-12-04 1993-05-11 G. D. Searle & Co. Chromonyl/chromonylalkyl-N-terminal amino hydroxy
US5231111A (en) * 1989-12-04 1993-07-27 G. D. Searle & Co. Imidazolyl/imidazolylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
US5217989A (en) * 1989-12-04 1993-06-08 G. D. Searle & Co. Benothiophenyl/benzothiophenylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
US5179102A (en) * 1989-12-04 1993-01-12 G. D. Searle & Co. Naphthyridinyl/naphthyridinylalkyl-n-terminal anino hydroxy β-amino acid derivatives
US5223532A (en) * 1989-12-04 1993-06-29 G. D. Searle & Co. Chromonyl/chromonylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino derivatives
US5223514A (en) * 1989-12-04 1993-06-29 G. D. Searle & Co. Quinolinyl/quinolinylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
IE66574B1 (en) * 1989-12-04 1996-01-24 Searle & Co Heterocyclic acyl aminodiol beta-amino acid derivatives
US5216013A (en) * 1989-12-04 1993-06-01 G. D. Searle & Co. Aralkyl-N-terminal cycloalkoxy-C terminal amino hydroxy β-amino acid derivatives
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
RU2105005C1 (ru) * 1992-07-03 1998-02-20 Кумиай Кемикал Индастри Ко., Лтд. Конденсированное гетероциклическое производное, способ его получения и гербицидное средство
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
DE69327536T2 (de) * 1992-10-14 2000-07-06 Merck & Co Inc Fibrinogenrezeptor-antagonisten
WO1994013643A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having crf antagonist activity
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
DE69323768T2 (de) * 1992-12-17 1999-07-01 Pfizer Pyrrolopyrimidine als crf antagonisten
US5292900A (en) * 1992-12-18 1994-03-08 Abbott Laboratories O-substituted N-hydroxyurea derivatives
EP0638071B1 (en) * 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
PT1153603E (pt) * 1993-06-28 2007-01-31 Wyeth Corp Novos tratamentos utilizando derivados de fenetilamina
US5705646A (en) * 1993-09-30 1998-01-06 Pfizer Inc. Substituted pyrazoles as CRF antagonists
GB9408577D0 (en) * 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
ES2199251T3 (es) * 1994-06-15 2004-02-16 Otsuka Pharmaceutical Company, Limited Derivados benzoheterociclicos utilizables como moduladores de vasopresina o de oxitocina.
CA2192815C (en) * 1994-07-07 1999-05-11 Yuji Kogami Novel 2,3-dihydrobenzofuran derivative, method for producing the same, and use thereof
US6150402A (en) * 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
ATE210657T1 (de) * 1994-10-14 2001-12-15 Merck Patent Gmbh Zns wirksames (r)-(-)-2-(5-(4-fluorophenyl)-3- pyridylmethylaminomethyl)chroman
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
DE69622569T2 (de) * 1995-08-21 2003-01-16 Takeda Chemical Industries Ltd Quinoneverbindung, seine herstellung und anwendung.
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
WO1997029774A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6310107B1 (en) * 1997-02-27 2001-10-30 Takeda Chemical Industries, Ltd. Amine compounds, their production and use as amyloid-β production inhibitors
US6194407B1 (en) * 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6251936B1 (en) * 1998-05-12 2001-06-26 American Home Products Corporation Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
EP1087952B1 (en) * 1998-06-18 2004-06-02 Novartis AG Benzazole compounds and their use
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US6255324B1 (en) * 1998-11-25 2001-07-03 Ned D. Heindel Amino-and mercurio-substituted 4′,5'-dihydropsoralens and therapeutical uses thereof
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6410562B1 (en) * 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
US7045545B1 (en) * 1999-01-27 2006-05-16 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists
WO2000044737A1 (en) * 1999-01-27 2000-08-03 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7217321B2 (en) * 2001-04-06 2007-05-15 California Institute Of Technology Microfluidic protein crystallography techniques
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
WO2002042731A2 (en) * 2000-11-20 2002-05-30 Parallel Synthesis Technologies, Inc. Methods and devices for high throughput crystallization
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
EP1444224B1 (en) * 2001-08-14 2006-05-03 Eli Lilly And Company 3-substituted oxindole beta-3 agonists
MXPA04003087A (es) * 2001-10-04 2004-09-06 Wyeth Corp Derivados de cromano como ligados de 5-hidroxitriptamina-6.
US6569894B1 (en) * 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US20030105830A1 (en) * 2001-12-03 2003-06-05 Duc Pham Scalable network media access controller and methods
US20030134835A1 (en) * 2002-01-11 2003-07-17 Arthur Hancock Histamine-3 receptor ligands for diabetes conditions
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US20040009976A1 (en) * 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
AU2003291012A1 (en) * 2002-11-15 2004-06-15 Galileo Pharmaceuticals, Inc. Chroman derivatives for the reduction of inflammation symptoms
DE10341533A1 (de) * 2003-09-09 2005-03-31 Bayer Chemicals Ag Verfahren zur Herstellung von halogenhaltigen 4-Aminophenolen
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7516224B2 (en) * 2004-10-21 2009-04-07 Cisco Technology, Inc. Pseudowire termination directly on a router
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
US7593398B2 (en) * 2005-09-08 2009-09-22 Cisco Technology, Inc. Layer-two interworking applied to L2-L3 pseudowires
TW200815388A (en) * 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof

Also Published As

Publication number Publication date
CA2603900A1 (en) 2006-11-02
GT200600158A (es) 2006-11-28
MX2007013179A (es) 2008-01-16
AU2006239897A1 (en) 2006-11-02
WO2006116218A1 (en) 2006-11-02
EP1879875A1 (en) 2008-01-23
TW200716583A (en) 2007-05-01
CN101163689A (zh) 2008-04-16
US20060252825A1 (en) 2006-11-09
JP2008538581A (ja) 2008-10-30
PE20061319A1 (es) 2006-12-28
BRPI0610785A2 (pt) 2016-09-13
WO2006116218A8 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
AR055054A1 (es) Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina
BRPI0212137A2 (pt) diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas
ECSP067077A (es) Derivados de pirrolopiridina y su uso como antagonistas de crth2
TW200716512A (en) Processes for preparing cinacalcet hydrochloride crystal form I
WO2008101187A3 (en) Pro-drugs of peripheral phenolic opioid antagonists
IL190532A0 (en) Cyclic amine compounds and pesticidal compositions containing the same
SE0302811D0 (sv) Novel compounds
IL183133A0 (en) Dibenzyl amine compounds and derivatives
MA28798B1 (fr) Dérivés de triazolopyridinylsufanyle servant d'inhibiteurs de kinase MAP P38
TW200608973A (en) Rapamycin polymorph Ⅱ and uses thereof
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
HUS2200042I1 (hu) Növények megvédése kórokozóikkal szemben
IL180397A0 (en) Diamine derivatives, fungicidal compositions containing the same, and processes for the preparation thereof
EP1931313A4 (en) PROCESS FOR PREPARING POLYMERS WITH TERMINAL AMINGRUPPES USING PROTECTED AMINES
EG25547A (en) Process for the preparation of amines
IL213615A0 (en) N-(5-substituted-2-nitrophenyl)amine derivatives and methods for the preparation of 6-substituted-1-methyl-1-h-benzimidazole derivatives utilizing the same
MY136824A (en) Substituted benzoxazinones and uses thereof
TW200638932A (en) CCI-779 polymorph and use thereof
DK1928464T3 (da) Ny parenteral carbamazepin-formulering
UY29804A1 (es) Quinolinas de alquilnitrilo
PL1758569T3 (pl) Sole guanylohydrazonowe, kompozycje, sposoby ich wytwarzania i stosowania
AR037636A1 (es) Clorhidrato de venlafaxina monohidrato y metodos para su preparacion
TR200604882A3 (tr) Örülü esya imalati için tertibat.
DE602006001776D1 (de) Geschützte Piperazinogruppe enthaltende Organooxysilanverbindung und Herstellungsverfahren
TW200745053A (en) 9-Aminocarbonylsubstituted derivatives of glycylcyclines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal